Breast HER2
Breast Cancer
CommercialActive
Key Facts
About Mindpeak
Mindpeak is a Hamburg-based AI/ML company operating at the intersection of digital pathology and precision medicine. It has developed a suite of CE-marked, deep learning-based software products that automate the analysis of immunohistochemistry (IHC) and H&E-stained tissue samples, primarily for oncology biomarkers like PD-L1, HER2, and Ki-67. The company's value proposition centers on '0-click' integration, offering both standalone and deeply embedded solutions within partner laboratory information systems to improve pathologist efficiency and diagnostic consistency. Mindpeak appears to be in a commercial, revenue-generating stage, serving diagnostic labs, hospitals, and research institutions.
View full company profileTherapeutic Areas
Other Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Antifibrotic Therapy Program | MeCo Diagnostics | Pre-clinical |
| inPROBE for HER2 | SDS Optic | Clinical Investigation |
| ACT‑BC1 | Anthrocell | Preclinical |
| APA-1000 Breast Thermotherapy System | Medifocus | Phase III |
| Early‑Detection Breast Cancer Screening | Karkinos Healthcare | Market |
| Unnamed Breast Cancer Program | Click Therapeutics | Pilot/Phase 2 |
| Lerociclib (Lerocliclib) | Chemogenics BioPharma | Phase 3 |
| AT-017 | Asieris Pharmaceuticals | Not Specified |
| CDK2 inhibitor | Acellera | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| Maveropepimut-S (MVP-S) | BioVaxys | Clinical Evaluation |
| Cannabics® BRST-33 | CNBX Pharmaceuticals | Discovery |